John Libbey Eurotext

Innovations & Thérapeutiques en Oncologie

Innovations & Thérapeutiques en Oncologie

Oncology is undoubtedly one of the most innovating medical disciplines: in a few years it has taken on targeting of specific molecular abnormalities in cancer cells and their environment (angiogenesis and immunity), technological development of ionising radiation, design of new organisation of care for patients and of their care pathway, introduction of new funding methods for research and innovation, and many other things.

 

In order to make all of these avenues which have been developed available, Innovations & Thérapeutiques en Oncologie has set itself two main missions, which are:

 

  • To bring knowledge about the largest number of innovations in oncology, trying as accurately as possible to define their benefits, but also their restrictions and limitations.

  • To echo the everyday impact of both these innovations and also any new methods in clinical practice, new ways of using them and new areas of interest from specific clinical situations.

 

With its eyes set resolutely on the future, the six annual editions of this Journal will quickly find their home with all French speaking oncologists.

 

The Innovations & Thérapeutiques en Oncologie review has an editing committee comprised of successful professionals who are expert in their respective sectors. It can therefore offer you excellent content which will contribute to the development of the future of oncology.

Ahead of print

Innovations acquises

Article Daratumumab: the first anti-CD38 monoclonal antibody for the treatment of multiple myeloma
Cyrille Touzeau, Benjamin Hébraud, Xavier Leleu
Online since 22/08/2017

Sélection et décryptage

Article Sélection et décryptage

Online since 27/10/2017